Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action

Revista Brasileira de Psiquiatria

Volumn 30, Issue 3, 2008, Pages 271-280

  Zuardi, Antonio Waldo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cannabidiol; Cannabinoids; Cannabis; History; Therapeutic uses

Indexed keywords

AMISULPRIDE; ANTINEOPLASTIC AGENT; CANNABIDIOL; CANNABINOID; CANNABIS; CLOZAPINE; DIAZEPAM; DRONABINOL; HALOPERIDOL; IPSAPIRONE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROLEPTIC AGENT; ONDANSETRON; PLACEBO;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; CANCER THERAPY; CATALEPSY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; GRAND MAL EPILEPSY; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; REM SLEEP; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; CANNABIDIOL; CANNABIS; DIABETES MELLITUS; HUMANS; MENTAL DISORDERS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SCHIZOPHRENIA;

EID: 54249156391     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462008000300015     Document Type: Review

References (121)

1. Clarke CR, Watson DP. Botany of natural Cannabis medicines. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potential. New York: The Haword Interactive Healing Press; 2002. Chapter 1. p. 3-13.
2. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196-200.
3. Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963;19(12):2073-8.
4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646.
5. Mechoulam R, Gaoni Y. The absolute configuration of delta- 1tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967:1109-11.
6. Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. Science. 1970;169(945):611-2.
7. Russo E. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-46.
8. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci. 1999;65(6-7):573-95.
9. Mechoulam R, Hanus L. Cann abidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids. 2002;121(1-2):35-43.
10. Mechoulam RE, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S-19S.
11. Long L, Malone DT, Taylor DA. The pharmacological action of cannabidiol. Drug Future. 2005;30(7):747-53.
12. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers. 2007;4(8):1678-92.
13. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65(4):174-9.
14. Kubena R, Barry H 3rd. Stimulus characteristics of marihuana components. Nature. 1072;235(5338):397-8.
15. Perez-Reyes M, Timmons MC, Dauls KH, Wall ME. A comparison of the pharmacological activity in man of the intravenously administered delta9 - tetrahydrocannabinol, cannabinol and cannabidiol. Experientia. 1973;29(11):1368-9.
16. Hollister LE. Cannabidiol and cannabinol in man. Experientia. 1973;29(7):825-6.
17. Carlini EA, Santos M, Claussen U, Bieniek D, Korte F. Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa. Psychopharmacologia. 1970;18(1):82-93.
18. Karniol IG, Carlini EA. The content of (-) 9 -trans-tetrahydrocannabinol (9-thc) does not explain all biological activity of some Brazilian marihuana samples. J Pharm Pharmacol. 1972;24(10):833-4.
19. Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia. 1973;33(1):53-70.
20. Borgen LA, Davis WM. Cannabidiol interaction with delta9- tetrahydrocannabinol. Res Commun Chem Pathol Pharmacol. 1974;7(4):663-70.
21. Fernandes M, Schabarek A, Coper H, Hill R. Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia. 1974;38(4):329-38.
22. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol. 1974;28(1):172-7.
23. Hollister LE, Gillespie H. Interactions in man of delta-9- tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther. 1975;18(1):80-3.
24. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther. 1976;19(3):300-9.
25. Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther. 1981;249(1):137-46.
26. Zuardi AW, Karniol IG. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res. 1983;16(2):141-6.
27. Zuardi AW, Teixeira NA, Karniol IC. Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther. 1984;269(1):12-9.
28. Paton WD, Pertwee RG. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol. 1972;44(2):250-61.
29. Borys HK, Karler R. Cannabidiol and delta 9-tetrahydrocannabinol metabolism. In vitro comparison of mouse and rat liver crude microsome preparations. Biochem Pharmacol. 1979;28(9):1553-9.
30. Jones G, Pertwee RG. A metabolic interaction in vivo between cannabidiol and 1 -tetrahydrocannabinol. Br J Pharmacol. 1972;45(2):375-7.
31. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk E, Stadelmann AM. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta 9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27(6):799-810.
32. Levy S, McCallum NK. Cannabidiol and its pharmacokinetic interaction with delta1-tetrahydrocannabinol. Experientia. 1975;31(11):1268-9.
33. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia. 1981;37(10):1090-2.
34. Zuardi AW, Karniol IG. Interação farmacológica entre delta - 9 - THC e CBD, dos constituintes activos da cannabis sativa. Ciência e Cultura. 1984;36(3):386-94.
35. Carlini EA, Leite JR, Tanhauser M, Berardi AC. Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol. 1973;25(8):664-5.
36. Izquierdo I, Orsingher OA, Berardi AC. Effect of cannabidiol and other Cannabis sativa compounds on hippocampal seizures discharges. Psychopharmacologia. 1973;28(1):95-102.
37. Turkanis SA, Cely W, Olsen DM, Karler R. Anticonvulsant properties of cannabidiol. Res Communic Chem Pathol Pharmacol. 1974;8(2): 231-46.
38. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel G, Gagliardi R, Sanvito EL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175-85.
39. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1986;69(1):14.
40. Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia. 1973;33(1):53-70.
41. Davis WM, Borgen LA. Effects of cannabidiol and delta-9- tetrahydrocannabinol on operant behavior. Res Commun Chem Pathol Pharmacol. 1974;9(3):453-62.
42. Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacol (Berl). 1977;55(3):263-5.
43. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(8-9 Suppl):417S-27S.
44. Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993;26(2):213-7.
45. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305-13.
46. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76(3):245-50.
47. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett. 2006;580(18):4337-45.
48. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci. 1986;30(4):277-82.
49. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40(3):701-8.
50. Zuardi AW, Karniol IG. Changes in the conditioned emotional response of rats induced by Δ9-THC, CBD and mixture of the two cannabinoids. Arquivos de Biologia e Tecnologia. 1983;26:391-7.
51. Musty RE, Conti LH, Mechoulam R. Anxiolytic properties of cannabidiol. In: Harvey DJ, editor. Marihuana '84. Proceedings of the Oxford Symposium on Cannabis. Oxford, UK: IRL Press Limited; 1984. p. 713-9.
52. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther. 1990;253(3):1002-9.
53. Guimarães FS, Chiaretti TM, Graeff F, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990;100(4):558-9.
54. Silveira Filho NG, Tufik S. Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Res Commun Psychol Psychiatry Behav. 1981;6:25-6.
55. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1466-71.
56. Zuardi AW, Cosme RA, Graeff FG et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7:82-8.
57. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417-26.
58. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt S, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire P. Distinct efeects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2008. (In press).
59. Rottanburg D, Robins AH, Ben-Aire O, Teggin A, Elk R. Cannabis associated psychosis with hypomaniac feature. Lancet. 1982;2(8312):1364-6.
60. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl). 1991;104(2):260-4.
61. Moreira FA, Guimarães FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 2005;512(2-3):199-205.
62. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology. 2006;31(4):795-803.
63. Zuardi AW, Guimarães FS, Guimarães VM. Cannabidiol: possible therapeutic application. In: Grotenhermen F, Russo E, Varo RN, editors. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. New York: The Haword Interactive Healing Press; 2002. p. 359-69.
64. Guimarães VM, Zuardi AW, Del Bel EA, Guimarães FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 2004;75(5):633-8.
65. Schneider U, Borsutzky M, Seifert J, Leweke FM, Huber TJ, Rollnik JD, Emrich HM. Reduced binocular depth inversion in schizophrenic patients. Schizophr Res. 2002;53(1-2):101-8.
66. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav. 2000;66(1):175-81.
67. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.
68. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39(4):421-9.
69. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485-6.
70. Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-6.
71. Leweke F, Koethe D, Gerth CW, et al. Double blind, controlled clinical trial of cannabidiol monotherapy versus amisulpiride in the treatment of acutely psychotic schizophrenia patients. Schizophr Bull. 2007;33(2):310.
72. Sandyk R, Consroe P, Stern L, Snider SR, Bliklen D. Preliminary trial of cannabidiol in Hantington's disease. In: Chesher G, Consroe P, Musty R, editors. Marijuana: an international research report. National campaign against drug monograph series no 7. Canberra: Australian Government Publishing Service; 1988. p.157-62.
73. Martin BR, Mechoulam RJ, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci. 1999;65(6-7):573-95.
74. Hampson AJ, Grimaldi M, Axelrod, Wink D. Cannabidiol and delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268-73.
75. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19(1-2):96-107.
76. Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134(1):162-70.
77. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci. 2007;26(4):843-51.
78. Hermann D, Sartorius A, Welzel H, Walter S, Skopp G, Ende G, Mann K. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry. 2007;61(11):1281-9.
79. Zuardi AW, Crippa JAS, Hallak JEC, Pinto JP, Nisihara MHC, Rodrigues GGR, Dursun SM, Tumas V. Cannabidiol for the treatment of psychosis in Parkinson's disease: possible mechanisms of actions. J Psychopharmacology. 2008 (in press).
80. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-41.
81. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med. 2006;84(3):253-8.
82. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett. 2006;399(1-2):91-5.
83. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol. 2007;151(8):1272-9.
84. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci. 2007;27(36):9537-44.
85. Formukong EA, Evans AT, Evans FJ. Analgesic and anti-inflammatory activity of constituents of cannabis sativa L. Inflammation. 1998;12(4):361-71.
86. Watzl B, Scuderi P, Watson RR. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-7.
87. Srivastava MD, Srivastava BI, Brouhard B. Delta-9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmachology. 1998;40(3):179-85.
88. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldman M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000;97(17):9561-6.
89. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(3):294-9.
90. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1-3):75-83.
91. Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett. 2003;346(1-2):61-4.
92. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H, Ikeda T, Inui K, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport. 2004;15(15):2381-5.
93. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke. 2005;36(5):1077-82.
94. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem. 2007;102(5):1488-96.
95. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology. 2007;52(4):1079-87.
96. Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, Beeri R, Pugatsch T, Tarsish E, Lotan C. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293(6):H3602-7.
97. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity. 2006;39(2):143-51.
98. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008;54(1):244-9.
99. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168(1):235-44.
100. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ. Physiol. 2007;293(1):H610-9.
101. Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of Delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293(16):795-7.
102. Doblin RE, Kleinman MA. Marijuana as antiemetic medicine: a survey of oncologists experiences and attitudes. J Clin Oncol. 1991;9(7):1314-9.
103. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven, CT: Yale University Press; 1997.
104. Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport. 2002;13(5):567-70.
105. Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl). 2004;171(2): 156-61.
106. Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav. 2006;87(1):66-71.
107. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl). 2008;196(3):389-95.
108. Jacobsson SO, Rongård E, Stridh M, Tiger G, Fowler CJ. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol. 2000;60(12):1807-13.
109. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004;308(3): 838-45.
110. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006;70(3):897-908.
111. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptorin-dependent mechanism. Br J Pharmacol. 2005;144(8):1032-6.
112. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):1375-87.
113. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6(11):2921-7.
114. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: V Di Marzo, editor. Cannabinoids. Kluwer Academic/ Plenum Publishers; 2004. p. 32-83.
115. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613-23.
116. Pertwee RG.The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215.
117. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092-101.
118. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde D, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845-52.
119. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8): 1037-43.
120. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology. 2008; [Epub ahead of print].
121. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A. 2006;103(20): 7895-900.